AIMS: The selective endothelin (ET) A receptor antagonist atrasentan has been shown to lower albuminuria in North American and Asian patients with type 2 diabetes and nephropathy. As drug responses for many drugs may differ between North American and Asian populations, we assessed the influence of geographical region on the albuminuria and fluid retention response to atrasentan. MATERIALS AND METHODS: Two 12-week double-blind randomized controlled trials were performed with atrasentan 0.75 or 1.25 mg/day versus placebo in patients with type 2 diabetes and nephropathy. The efficacy endpoint was the percentage change in albuminuria. Body weight change, a proxy of fluid retention, was used as safety endpoint. Pharmacodynamics were determined in Asians (N = 77) and North Americans (N = 134). Atrasentan plasma concentration was measured in 161 atrasentan treated patients. RESULTS: Mean albuminuria reduction in Asian compared to North American patients was respectively -34.4% versus -26.3% for 0.75 mg/day (p = 0.44) and -48.0% vs. -28.9% for 1.25 mg/day (p = 0.035). Body weight gain did not differ between North American and Asian populations. Atrasentan plasma concentrations were higher in Asians compared to North Americans and correlated with albuminuria response (7.2% albuminuria reduction per doubling atrasentan concentration; p = 0.024). Body surface area (beta = -1.09 per m2 ; p < 0.001) and bilirubin, as a marker of hepatic organic anion transporter activity, (beta = 0.69 per mg/dL increment; p = 0.010) were independent determinants of atrasentan plasma concentration: correction by body surface area and bilirubin left no significant difference in plasma concentration between Asian and North American populations. CONCLUSION: The higher exposure and albuminuria reduction of atrasentan in Asian patients is not associated with more fluid retention suggesting that Asian patients are less sensitive to atrasentan-induced sodium retention..
AD - Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Postbox 30001, 9700, RB, Groningen, The Netherlands.AIMS: The selective endothelin (ET) A receptor antagonist atrasentan has been shown to lower albuminuria in North American and Asian patients with type 2 diabetes and nephropathy. As drug responses for many drugs may differ between North American and Asian populations, we assessed the influence of geographical region on the albuminuria and fluid retention response to atrasentan. MATERIALS AND METHODS: Two 12-week double-blind randomized controlled trials were performed with atrasentan 0.75 or 1.25 mg/day versus placebo in patients with type 2 diabetes and nephropathy. The efficacy endpoint was the percentage change in albuminuria. Body weight change, a proxy of fluid retention, was used as safety endpoint. Pharmacodynamics were determined in Asians (N = 77) and North Americans (N = 134). Atrasentan plasma concentration was measured in 161 atrasentan treated patients. RESULTS: Mean albuminuria reduction in Asian compared to North American patients was respectively -34.4% versus -26.3% for 0.75 mg/day (p = 0.44) and -48.0% vs. -28.9% for 1.25 mg/day (p = 0.035). Body weight gain did not differ between North American and Asian populations. Atrasentan plasma concentrations were higher in Asians compared to North Americans and correlated with albuminuria response (7.2% albuminuria reduction per doubling atrasentan concentration; p = 0.024). Body surface area (beta = -1.09 per m2 ; p < 0.001) and bilirubin, as a marker of hepatic organic anion transporter activity, (beta = 0.69 per mg/dL increment; p = 0.010) were independent determinants of atrasentan plasma concentration: correction by body surface area and bilirubin left no significant difference in plasma concentration between Asian and North American populations. CONCLUSION: The higher exposure and albuminuria reduction of atrasentan in Asian patients is not associated with more fluid retention suggesting that Asian patients are less sensitive to atrasentan-induced sodium retention..
PY - 2017 SN - 1463-1326 (Electronic)